Siewert S, Kieslich K, Braun M, Dabrock P (2023)
Publication Type: Book chapter / Article in edited volumes
Publication year: 2023
Publisher: Springer Science and Business Media B.V.
Series: SpringerBriefs in Philosophy
Pages Range: 47-53
DOI: 10.1007/978-3-031-16004-2_6
When talking about public participation and the regulatory decision-making process, it is crucial to think about the right time and purpose to involve different stakeholders. The chapter explores circumstantial prerequisites for participatory approaches on the basis of a more recent case study: synthetically produced vaccines against the coronavirus SARS-CoV-2. The COVID-19 pandemic made synthetic biology a global issue—in a way that is unprecedented. Yet, its implementation also poses questions for participation for future vaccine and drug production: How can and should we engage the public on ethical questions of emerging and potentially disruptive technologies during a public health emergency? How do certain focus areas, particularly communication and resources, data management and training, provide valuable avenues in dealing with future emergency applications of SB?
APA:
Siewert, S., Kieslich, K., Braun, M., & Dabrock, P. (2023). Case Study: COVID-19 Vaccine Development. In (pp. 47-53). Springer Science and Business Media B.V..
MLA:
Siewert, Stephanie, et al. "Case Study: COVID-19 Vaccine Development." Springer Science and Business Media B.V., 2023. 47-53.
BibTeX: Download